Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma...read more
Theseus Pharmaceuticals, a preclinical biotech developing pan-variant kinase inhibitors for solid tumors, raised $160 million by offering 10 million shares at $16, the high end of the $14 to $16 range. The company sold 20% more shares than anticipated, according...read more
Updated Monday, 10/4. In the first full week of October, seven IPOs are slated to raise $2.0 billion, led by two fitness companies. Fitness chain Life Time Group Holdings (LTH) plans to raise $901 million at a $4.1 billion market...read more
Theseus Pharmaceuticals, a preclinical biotech developing pan-variant kinase inhibitors for solid tumors, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14...read more
US IPO Weekly Recap: Healthcare and Canadian crosslistings lead an 8 IPO week
Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma...read more
Preclinical cancer biotech Theseus Pharmaceuticals prices upsized IPO at $16 high end
Theseus Pharmaceuticals, a preclinical biotech developing pan-variant kinase inhibitors for solid tumors, raised $160 million by offering 10 million shares at $16, the high end of the $14 to $16 range. The company sold 20% more shares than anticipated, according...read more
US IPO Week Ahead: New issuers work up a sweat in a fitness-led 7 IPO week
Updated Monday, 10/4. In the first full week of October, seven IPOs are slated to raise $2.0 billion, led by two fitness companies. Fitness chain Life Time Group Holdings (LTH) plans to raise $901 million at a $4.1 billion market...read more
Solid tumor biotech Theseus Pharma sets terms for $125 million IPO
Theseus Pharmaceuticals, a preclinical biotech developing pan-variant kinase inhibitors for solid tumors, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14...read more